Merck & Company Inc (MRK)vsOmada Health, Inc. Common Stock (OMDA)
MRK
Merck & Company Inc
$148.10
-1.88%
HEALTHCARE · Cap: $355.10B
OMDA
Omada Health, Inc. Common Stock
$20.69
-3.18%
HEALTHCARE · Cap: $1.31B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 21391% more annual revenue ($66.57B vs $309.76M). MRK leads profitability with a 4.8% profit margin vs 1.4%. OMDA trades at a lower P/E of 31.0x. OMDA earns a higher WallStSmart Score of 37/100 (F).
MRK
Hold36
out of 100
Grade: F
OMDA
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-77.2%
Fair Value
$83.04
Current Price
$148.10
$65.06 premium
Intrinsic value data unavailable for OMDA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Revenue surging 43.1% year-over-year
Areas to Watch
Trading at 8.7x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
1.4% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : OMDA
The strongest argument for OMDA centers on Revenue Growth. Revenue growth of 43.1% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : OMDA
The primary concerns for OMDA are P/E Ratio, EPS Growth, Market Cap. Thin 1.4% margins leave little buffer for downturns.
Key Dynamics to Monitor
MRK profiles as a value stock while OMDA is a hypergrowth play — different risk/reward profiles.
OMDA is growing revenue faster at 43.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
OMDA scores higher overall (37/100 vs 36/100) and 43.1% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Omada Health, Inc. Common Stock
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Omada Health, Inc. provides a range of virtual care programs in the United States. The company is headquartered in San Francisco, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?